Benchmark reiterates Buy rating on IMAX stock, cites strong Q3 box office

Benchmark maintained its Buy rating and $32.00 price target on IMAX Corporation (NYSE:IMAX), citing strong stock momentum and expectations to exceed upcoming Q3 consensus estimates, with global box office already nearing $240 million. The firm highlighted IMAX's brand resonance, sustained market share gains, and strong slate visibility and studio alignment extending into 2026. This positive outlook is further bolstered by recent operational successes, including a record market share for the 'Superman' debut, an expanded credit facility to $375 million, and new screen expansion initiatives in the US and Australia, reinforcing IMAX's growing influence in the premium format market.

Analysis

IMAX Corporation (NYSE:IMAX) is exhibiting significant operational and financial momentum, underpinned by a reiterated Buy rating and a $32.00 price target from Benchmark. The stock's recent 7.73% gain, pushing it near its 52-week high, is supported by fundamental drivers including upward earnings revisions from three analysts. Benchmark anticipates IMAX will surpass the Q3 2025 consensus box office estimate of $286 million, with global receipts already tracking at approximately $240 million. This performance is attributed to the brand's strong consumer resonance and sustained market share gains, evidenced by the record IMAX market share for the "Superman" debut, which grossed $30.4 million globally. The company's growth outlook is further solidified by strong visibility into a "record Q4 slate" and "unprecedented studio alignment" through 2026. Strategically, IMAX is securing its future growth trajectory by expanding its credit facility to $375 million for enhanced financial flexibility and pursuing network expansion through new partnerships with Apple Cinemas in the U.S. and HOYTS in Australia.

Key Decisions for Investors

• Given the strong analyst support, upward earnings revisions, and a price target of $32.00, investors could view the current price as a potential entry point, capitalizing on the positive operational momentum.
• Investors should closely monitor upcoming box office data against the Q3 consensus of $286 million, as continued outperformance is a key pillar of the current bullish thesis.
• While the outlook is positive, future performance is highly contingent on the execution of its film slate and global expansion plans; therefore, monitoring progress on new theater openings with partners like Apple Cinemas and HOYTS is critical.